Dutta et al. evaluated its combination with anti-PD-L1 therapy and interestingly found that the combination significantly reduced tumor growth, which was associated with enhanced CD8+ T cell infiltration, decreased MDSC and anti-inflammatory macrophages, transforming the TME from being immunologically ‘cold’ to ‘hot’ [331]. This evidence concerns the gene CD8A and neoplasm.